DrugPatentWatch Database Preview

Infigratinib phosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for infigratinib phosphate and what is the scope of patent protection?

Infigratinib phosphate is the generic ingredient in one branded drug marketed by Qed Therap and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Infigratinib phosphate has one hundred and twenty-eight patent family members in forty countries.

Summary for infigratinib phosphate

International Patents:	128
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	23
Patent Applications:	13
DailyMed Link:	infigratinib phosphate at DailyMed

US Patents and Regulatory Information for infigratinib phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Qed Therap	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		RX	Yes	No
Qed Therap	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		RX	Yes	Yes
Qed Therap	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		RX	Yes	No			Y	Y
Qed Therap	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		RX	Yes	Yes			Y	Y
Qed Therap	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		RX	Yes	Yes			Y
Qed Therap	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		RX	Yes	No				Y

International Patents for infigratinib phosphate

Country	Patent Number	Estimated Expiration
Serbia	59270
Philippines	12016501039
Tunisia	SN06411
China	111269186
European Patent Office	3079667
Peru	20120252